The Jenex Corporation, in Collaboration with UHN’s Techna Institute, Reports Promising Initial Results on Zika Virus Testing with TherOZap(TM)

Toronto, Ontario–(Newsfile Corp. – October 12, 2017) - The Jenex Corporation (TSXV: JEN.H) (“Jenex” or the “Company”), a progressive medical device technology company, today announces that it has received promising initial results on the Zika virus testing with TherOZap.

Dr. Alyson Kelvin at UHN reported the following:

“To evaluate the effectiveness of the Jenex TherOZap device against the infectivity of Zika virus, cells were infected with a range of Zika virus doses and treated with the Jenex device with heat. In the cells that received the lowest viral dose, initial results showed infected cells that had been treated with the Jenex TherOZap device had a markedly lower cytopathic effect compared to infected cells that did not receive treatment. These preliminary results need to be confirmed through repeated testing as well as by measurement of virus viability. Cytopathic effect is a measure of cellular pathogenesis and cellular viability in relation to viral infection; results of a viral replication assay and measurements of live viral activity are pending.”

Mr. Rob Fia, CEO, commented:

We are pleased with the initial test results on the Zika Virus with our patent pending TherOZap™ technology. Jenex is excited about these initial tests results and we look forward to further data as it becomes available from Techna Institute at UHN. Jenex will have more to report to over the next several weeks.”

About Jenex:

Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs.  Clear and healthy skin for all is at the core of Jenex’s philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments.  The Company’s breakthrough proprietary technology delivers effective, non-invasive and pain free skin care.

Jenex received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). Jenex received approval for the above claims from FDA (United States) in 1997.

The Jenex Corporation trades on the NEX (TSXV: JEN.H). For more information visit: www.thejenexcorporation.com or www.therozap.com.

About Techna Institute:

Techna is an institute of the University Health Network, in collaboration with the University of Toronto, focused on the accelerated development and exploitation of technology for improved health. Techna is designed to shorten the time interval from technology discovery and development to application for the benefit of patients and the health care system. It also stimulates and facilitates the innovation cycle through a continuum of clinically driven innovation, technology & process development, and translational research. For more information visit: technainstitute.com.

FORWARD LOOKING STATEMENTS

Certain statements in this news release constitute “forward-looking” statements. These statements relate to future events or the Company’s future performance and include laboratory tests involving TherOZap™, as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. In addition to other risks, the Company may not complete the commercialization or marketing of its products as described in this news or attract capital in the future. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

For further information please contact: The Jenex Corporation Rob Fia CEO & Chairman rfia@thejenexcorporation.com

NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES

UHN Start-up AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Cystinosis

Cystinosis Program Becomes Company’s Fourth Gene Therapy  for Lysosomal Storage Disorders

Cambridge, MA, October 4, 2017 – AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, today announced the expansion of its pipeline to cystinosis. This program becomes AVROBIO’s fourth gene therapy for lysosomal storage disorders (LSDs), and with an anticipated IND filing later this year is expected to enter the clinic in early 2018. The cystinosis program was licensed from GenStem Therapeutics, Inc. Terms of the license agreement were not disclosed.

“This cystinosis program is a strong strategic fit with our pipeline,” said Geoff MacKay, AVROBIO’s President and Chief Executive Officer. “We are pleased to partner with Dr. Stephanie Cherqui and her team at the University of San Diego (UCSD), as well as with GenStem Therapeutics, Inc. as we share their vision of developing a novel and potentially transformative gene therapy for the treatment of patients with cystinosis.”

“We are extremely pleased to partner with AVROBIO. As a leader in gene therapies for lysosomal storage disorders, they will substantially accelerate the development and commercialize our novel treatment for cystinosis, said Jeffrey Ostrove, Ph.D., Chief Executive Officer of GenStem Therapeutics, Inc.  “This will help bring a novel therapy to patients who suffer from this disease.”

Cystinosis, like all lysosomal storage disorders, is a progressive and potentially fatal metabolic disorder with an estimated incidence of 1 in 100,000 to 200,000 live births. Cystinosis is caused by a single-gene defect in the CTNS gene leading to the accumulation of an amino acid called cystine in all tissues and organs of the body including the kidneys, eyes, muscles, thyroid and pancreas. Patients with cystinosis have a wide range of symptoms depending on the age of onset and disease severity including renal Fanconi syndrome and renal failure by adolescence, sensitivity to light, blindness, severe muscle weakness, difficulty swallowing, and endocrinopathies including hypothyroidism and diabetes, and neurological defects.

The aim of AVROBIO’s investigational gene therapy to treat cystinosis is to deliver lasting and meaningful benefits for patients. The patient’s peripheral blood stem cells are extracted and genetically modified by adding a new, fully functional copy of the faulty gene. The modified cells, once delivered back into the patient via a one-time infusion, enable durable gene rescue of the progressive tissue injury, with the potential to significantly improve patient outcomes and eliminate burdensome and costly lifelong cysteamine treatments.

About AVROBIO, Inc.
AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical-stage company developing disruptive therapies that have the potential to transform patients’ lives with a single dose. The Company is focused on the development of its Phase 1 program in Fabry disease and pre-IND programs in cystinosis and Gaucher disease, while actively building a pipeline of therapies to treat Pompe disease and other rare and non-rare genetic diseases. AVROBIO also has an immuno-oncology gene therapy program. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON. For additional information, visit www.avrobio.com.

Media Inquiries:
Kirsten Dupuis
AVROBIO, Inc.
+1.617.914.8403
kirsten.dupuis@avrobio.com

Bauer Launches Innovative NeuroShield in Canada, Co-Invented by the Founder of UHN Spin-off Thornhill Medical

NeuroShield

Bauer, the world’s leading manufacturer of ice hockey equipment, recently launched the first athletic product clinically shown to help protect the brain from the inside during sports-related impacts. Continuing Bauer Hockey’s rich history of delivering game-changing technologies, the BAUER NeuroShield collar revolutionizes head protection with an innovative approach that delivers peer-reviewed scientific benefits.

The technology behind NeuroShield was discovered by Dr. David Smith, who was inspired by the woodpecker’s ability to withstand thousands of impacts daily and fly away unharmed. Woodpeckers have natural adaptions that protect their brains, which led Dr. Smith to look more closely at human physiology and head protection. Dr. Smith, along with Thornhill Medical founder, Dr. Joseph Fisher and Dr. Julian Bailes, performed the initial research looking to identify a product solution using the body’s own physiology to help stabilize the brain.

Bauer has licensed the NeuroShield technology from Q30 Innovations, LLC (Q30), a research and development company that acquired the rights to the underlying technology from Dr. Smith and Thornhill Medical. Dr. Bailes serves as medical advisor and is a shareholder in Q30. Q30 has sponsored studies conducted by researchers affiliated with leading academic and medical institutions, including Cincinnati Children’s Hospital Medical Center.

Over time impacts both large and small accumulate and can cause changes to the microstructure of the brain in athletes. NeuroShield is revolutionary because of its ability to provide an athlete with protection which reduces the likelihood that these changes will occur.

 DR. JULIAN BAILES, CHAIRMAN OF THE DEPARTMENT OF NEUROSURGERY AND CO-DIRECTOR OF NORTHSHORE UNIVERSITY HEALTH SYSTEM NEUROLOGICAL INSTITUTE

“Research shows that the brain can undergo changes as a result of sports-related impacts, even in the absence of a clinically-diagnosed concussion,” said Dr. Julian Bailes, Chairman of the Department of Neurosurgery and Co-Director of NorthShore University Health System Neurological Institute. “Over time impacts both large and small accumulate and can cause changes to the microstructure of the brain in athletes. NeuroShield is revolutionary because of its ability to provide an athlete with protection which reduces the likelihood that these changes will occur.”

The NeuroShield collar is worn around the neck and applies light pressure that mildly increases blood volume in the venous structures around the brain. This small and safe increase in volume helps reduce brain movement inside the skull, and as a result, key components of its microstructure, such as delicate nerve fibers, are better protected. This small increase in blood volume is similar to what occurs naturally when a person lies down or yawns.

According to the results of these published, peer-reviewed studies, when a player wears NeuroShield over the course of a season, advanced imaging shows no significant structural change to the brain as compared to those not wearing NeuroShield. The short- and long-term impacts of these structural changes to the brain are not fully understood at this time and continue to be studied. The NeuroShield collar does not prevent concussions.

Athletic performance was also measured to ensure it was not sacrificed as a result of a player wearing NeuroShield.  Athletes were subjected to more than 20 different tests including cardiorespiratory capacity, strength, reaction time, memory and other athletic functions. In each test, it was determined that the NeuroShield technology did not negatively impact their performance.

The NeuroShield collar is available now in select hockey stores in Canada. The collar is available in eight sizes based on neck size. NeuroShield can be worn in both helmeted and un-helmeted sports and is designed to complement and be compatible with equipment typically worn during play, including neck guards, shoulder pads and helmets. The collar is not yet available for sale in the United States.

The Canadian-recommended retail price is $199 (CAD). To learn more about NeuroShield and find a store near you, please visit www.neuroshield.ca.

About Thornhill Medical

Thornhill Medical makes innovative healthcare devices. Our founder, Dr. Joseph Fisher, is a world-renowned research scientist in the field of anesthesiology and cardiovascular intensive care. Since spinning off from the University Health Network in 2003, Thornhill Medical has built upon his expertise to develop and manufacture compact mobile emergency respiration and anesthesia devices.  Our full story can be found on our website www.thornhillmedical.com

 

About Bauer
Founded in 1927 in Kitchener, Ontario, Bauer has a long-standing history of commitment to research and development to help ensure both player safety and the ability to provide the highest level of value and performance.  In 2015, Bauer opened its state-of-the-art innovation center in Blainville, Quebec. Bauer continues to drive innovation that improves athlete performance on-ice, for all age groups, and all levels of play.

 

About Q30 Innovations

Q30 Innovations, LLC, is a global research and development company dedicated to finding innovative head safety solutions.  Q30 partners with leading independent science and medical institutions to design cutting-edge products that will protect athletes, soldiers and industrial workers.

For further information about Thornhill Medical please contact: Kipton Lade 416-597-1325, klade@thornhillmedical.com

Source: Thornhill Medical, Newswire

UHN Start-up AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Pompe Disease

Pre-Clinical Program Becomes Company’s Third GeneTherapy
for Lysosomal Storage Disorders

Pre-Clinical Proof-of-Concept Demonstrated

Cambridge, MA, September 20, 2017 – AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, today announced the expansion of its pipeline to Pompe disease. This pre-clinical program becomes AVROBIO’s third gene therapy for Lysosomal Storage Disorders (LSDs), following on the heels of the Company’s Phase 1 Fabry program and pre-Phase 1/2 Gaucher program. AVROBIO’s gene therapy for Pompe disease utilizes a proprietary lysosomal targeting sequence to deliver high levels of enzyme to lysosomes.

“Pompe disease is a serious lysosomal storage disorder with significant unmet need; our gene therapy is designed to deliver therapeutically relevant levels of enzyme to treat these patients,” said Geoff MacKay, AVROBIO’s President and Chief Executive Officer. “By combining our state-of-the-art gene therapy platform with our proprietary lysosomal targeting technology, AVROBIO is advancing a truly novel solution to treat patients with this debilitating disease.”

Pompe disease, also known as glycogen storage disease type II and/or acid maltase deficiency, is a progressive and often fatal neuromuscular disorder affecting 1:40,000 people worldwide. This inherited disorder is caused by a single-gene defect leading to the absence or partial deficiency of the lysosomal enzyme, acid alpha-glucosidase (GAA). The dysfunctional enzyme causes the pathological storage of glycogen in various cells throughout the body. Patients with Pompe disease experience a wide range of clinical symptoms including significant muscle weakness affecting the ability to walk and respiratory insufficiency affecting the ability to breathe. Pompe disease is one of the more common lysosomal storage disorders affecting people of all ages and ethnicities.

The aim of AVROBIO’s investigational gene therapy to treat Pompe disease is to deliver lasting and meaningful benefits for patients. The patient’s peripheral blood stem cells are extracted and genetically modified by adding a new, fully functional copy of the faulty gene. The modified cells are then delivered back into the patient via a one-time infusion. A durable elevation of endogenous enzyme is expected, with the potential to significantly improve patient outcomes and eliminate burdensome and costly lifelong biweekly intravenous infusions of enzyme replacement therapy.

About AVROBIO, Inc.

AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical-stage company developing disruptive therapies that have the potential to transform patients’ lives with a single dose. The Company is focused on the development of its Phase 1 program in Fabry disease and pre-Phase 1/2 program in Gaucher disease, while actively building a pipeline of therapies to treat Pompe disease and other rare and non-rare genetic diseases. AVROBIO also has an immuno-oncology gene therapy program. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON. For additional information, visit www.avrobio.com.

Media Inquiries:
Kirsten Dupuis
AVROBIO, Inc.
+1.617.914.8403
kirsten.dupuis@avrobio.com

SOURCE: Avrobio.com

UHN Start-up MyndTec Announces 510(k) Clearance for MyndMove® Therapy for Individuals with Upper Extremity Paralysis

MISSISSAUGA, ONSept. 8, 2017 /CNW/ – MyndTec, an award-winning Canadian medical technology company announced today it has received 510(k) clearance to market its landmark product MyndMove®.  MyndTec is a pioneer in the treatment of arm and hand paralysis caused by stroke or spinal cord injury.

“This is a major milestone in the evolution of our company,” said MyndTec Founder Dr. Milos R. Popovic.  “We are delighted that we can now offer this life-changing therapy to patients in the U.S. with upper extremity paralysis.”

MyndTec intends to initiate a pilot launch of MyndMove® into the U.S. market which complements a product introduction already underway in Canada with a previously announced approval from Health Canada.

MyndMove® Therapy is a functional electric stimulation (FES) based intervention.  The system offers therapists the ability to assist individuals with upper limb paralysis to improve voluntary control of their arms and hands. The MyndMove® therapy system offers over 30 FES protocols that therapists use to enable meaningful controlled movements via proprietary stimulation technology.

About MyndTec

MyndTec Inc. (formerly Simple Systems Inc.) is a privately held medical technology company located in Mississauga, Ontario, that develops and commercializes innovative therapeutic medical devices designed to improve function, maximize independence and enhance quality of life.  MyndTec was founded in 2008 as Simple Systems Inc., to commercialize technology developed by Dr. Milos R. Popovic and his colleagues at the Toronto Rehabilitation Institute-University Health Network and the Institute of Biomaterials and Biomedical Engineering at the University of Toronto.

For more information on MyndTec and MyndMove® and authorized indications, please visit http://www.myndtec.com. The contents of the website are specifically not incorporated by reference in this press release.

SOURCE MyndTec Inc. 

For further information: Steven Plymale, MyndTec Inc., 905-363-0564, Steven.Plymale@myndtec.com

RELATED LINKS
www.myndtec.com

UHN’s Techna Institute, in Collaboration with Jenex, to release initial results on Zika virus deactivation testing

For Immediate Release

NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES

Jenex Reports Expected Date of Test Results for TherOZap™ at Inactivating the Zika Virus

Toronto, Ontario – (September 14, 2017) The Jenex Corporation (“Jenex”, or the “Company”, NEX: JEN.H), a progressive medical device technology company, would like to report that the Techna Institute at UHN has informed Jenex that the initial data results for TherOZap at inactivating the Zika virus are expected to be received during the week of October 2nd with an outside reporting date during the second week of October.  Techna Institute has informed Jenex that additional time may be required outside of the first week of October if necessary to provide the data.  Jenex expects to report additional information on the various tests being performed with the TherOZapas it receives the information from Techna Institute to determine the TherOZapability to inactivate the Zika virus.

Rob Fia, CEO, commented:

“We would like to thank our shareholders for demonstrating patience while awaiting the testing of TherOZapwith Techna Institute at UHN.  Jenex has added additional testing parameters which has caused some of the delays as the Company felt it was prudent to investigate testing the device as broadly as possible.  We are as excited as our shareholders to receive the initial tests results and we ask that shareholders continue to be patient as we expect additional information related to testing TherOZap throughout the rest of 2017.”

About Jenex:

Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs.  Clear and healthy skin for all is at the core of Jenex’s philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments.  The Company’s breakthrough proprietary technology delivers effective, non-invasive and pain free skin care. The Jenex Corporation trades on the NEX (NEX: JEN.H). For more information visit: www.thejenexcorporation.com or www.therozap.com

 

About Techna Institute:

Techna is an institute of the University Health Network, in collaboration with the University of Toronto, focused on the accelerated development and exploitation of technology for improved health.Techna is designed to shorten the time interval from technology discovery and development to application for the benefit of patients and the health care system. It also stimulates and facilitates the innovation cycle through a continuum of clinically driven innovation, technology & process development, and translational research. For more information visit: technainstitute.com

About University Health Network:

University Health Network (UHN) is a major landmark in Canada’s healthcare system and a teaching partner of the University of Toronto. UHN consists of Toronto General and Toronto Western Hospitals, the Princess Margaret Cancer Centre, Toronto Rehabilitation Institute and the Michener Institute for Education at UHN. The scope of research and complexity of cases at University Health Network has made it a national and international source for discovery, education and patient care. It has the largest hospital-based research program in Canada, with major research in cardiology, transplantation, neurosciences, oncology, surgical innovation, infectious diseases, genomic medicine and rehabilitation medicine. For more information visit: www.uhn.ca

 

FORWARD LOOKING STATEMENTS

 

Certain statements in this news release constitute “forward-looking” statements. These statements relate to future events or the Company’s future performance and include tests involving the Company’s TherOZap™ technology and expected test results for the technology at inactivating the Zika virus as described in the news release.  All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements.  In addition to other risks, the Company’s tests involving TherOZap™ may prove to be unsuccessful against the Zika virus and the Company may be unable to complete the consumer product TherOZap™ technology. Further, the Company may not complete the tests on the schedule it expects as described in this news release or attract capital for marketing to ramp up sales or establish recurring revenue in the future to generate cash flow for the Company. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks.  Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

For Further information please contact:

The Jenex Corporation

Rob Fia

CEO & Chairman

rfia@thejenexcorporation.com

 
 

 

 

We’re hiring: Commercialization Intern (8 months full-time, Oct-May)

Are you a graduated student with an interest in commercialization? Experience with market analysis? A scientific background? Join the TDC team as our TDC Commercialization Intern starting this Fall, 2017.

Please note this opportunity is not available to current students.

Job Title:  Commercialization Intern (8 months full-time, Oct-May)
Company Name:  University Health Network, Office of Technology Development & Commercialization
Website: http://tdc.uhnresearch.ca/
Location:   MaRS Discovery District, 101 College Street
Interview Date:   ASAP
Address Cover letter to: Allison Aab Allison.Aab@uhnresearch.ca
Deadline: Extended to Oct 10, 2017
HOW TO APPLY:   Email resume and cover letter to Allison.Aab@uhnresearch.ca with subject “Commercialization Internship”
Description: The intern will work with the team at TDC responsible for commercializing innovations created at University Health Network, which range from life science discoveries, to clinical and research tools, and medical devices and software.The responsibilities of the intern will include: assessing new invention disclosures, creating business plans and commercialization strategies, supporting research business services, and possibly also drafting grant applications.

Specific activities will include:

-Assessing new invention disclosures for market feasibility;

-Conducting prior art searches and providing an opinion on patentability;

-Researching markets to find competitors and potential licensees and creating commercialization strategies based on product, competitive advantage, market size and forces, team strengths, and patent position;

-Identifying commercialization grant opportunities and working with Principal Investigators and Licensing Professionals to write and submit commercialization grants;

-Researching capital cost requirements, performing financial analyses, and creating business plans for start-ups;

-Assisting with the review of Confidentiality Agreements.

The ideal candidate will have a scientific or technical background (e.g. PhD or Masters in life or physical sciences, engineering or computer science), a business background (completed/in progress MBA, BBA, or equivalent), and familiarity with patents.

 

Tribute to Dr. Michael Sharpe, UHN Researcher, for Contribution to the Advancement of Radiation Therapy

TDC is proud to have helped enable an important advance in radiation therapy and radiation therapy training, and to honor the memory of one of our great inventors, Dr. Michael Sharpe.

In this video, UHN outlines the impact of the automatic treatment planning innovations it recently licensed to RaySearch, enabling algorithms from Princess Margaret Cancer Center to be integrated into RayStation.

UHN Start-up VistaGen Receives Notice of Allowance from U.S. Patent and Trademark Office for U.S. Patent regarding Breakthrough Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potential to Treat Autoimmune Disorders and Cancer

SOUTH SAN FRANCISCO, CA — (Marketwired) — 08/08/17 – VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/359,517 regarding proprietary methods for producing hematopoietic precursor stem cells, which are stem cells that give rise to all of the blood cells and most of the bone marrow cells in the body, with potential to impact both direct and supportive therapy for autoimmune disorders and cancer.

The breakthrough technology covered by the allowed U.S. patent was discovered and developed by distinguished stem cell researcher, Dr. Gordon Keller, Director of the UHN’s McEwen Centre for Regenerative Medicine in Toronto, one of the world’s leading centers for stem cell and regenerative medicine research and part of the University Health Network (UHN), Canada’s largest research hospital. Dr. Keller is a co-founder of VistaGen and a member of the Company’s Scientific Advisory Board. VistaGen holds an exclusive worldwide license from UHN to the stem cell technology covered by the allowed U.S. patent.

“We are pleased to report that the USPTO has allowed another important U.S. patent relating to our stem cell technology platform, stated Shawn Singh, Chief Executive Officer of VistaGen. “Because the technology under this allowed patent involves the stem cells from which all blood cells are derived, it has the potential to reach the lives of millions battling a broad range of life-threatening medical conditions, including cancer, with CAR-T cell applications and foundational technology we believe ultimately will provide approaches for producing bone marrow stem cells for bone marrow transfusions. As we continue to expand the patent portfolio of VistaStem Therapeutics, our stem cell technology-focused subsidiary, we enhance our potential opportunities for additional regenerative medicine transactions similar to our December 2016 sublicense of cardiac stem cell technology to BlueRock Therapeutics, while focusing VistaStem’s internal efforts on using stem cell technology for cost-efficient small molecule drug rescue to expand our drug development pipeline.”

About VistaGen
VistaGen Therapeutics, Inc. (NASDAQ: VTGN), is a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders. VistaGen’s lead CNS product candidate, AV-101, is in Phase 2 development, initially as a new generation oral antidepressant drug candidate for major depressive disorder (MDD). AV-101′s mechanism of action is fundamentally different from all FDA-approved antidepressants and atypical antipsychotics used adjunctively to treat MDD, with potential to drive a paradigm shift towards a new generation of safer and faster-acting antidepressants. AV-101 is currently being evaluated by the U.S. National Institute of Mental Health (NIMH) in a small Phase 2 monotherapy study in MDD being fully funded by the NIMH and conducted by Dr. Carlos Zarate Jr., Chief, Section on the Neurobiology and Treatment of Mood Disorders and Chief of Experimental Therapeutics and Pathophysiology Branch at the NIMH. VistaGen is preparing to launch a 180-patient Phase 2 study of AV-101 as an adjunctive treatment for MDD patients with an inadequate response to standard, FDA-approved antidepressants. Dr. Maurizio Fava of Harvard University will be the Principal Investigator of the Company’s Phase 2 adjunctive treatment study. AV-101 may also have the potential to treat multiple CNS disorders and neurodegenerative diseases in addition to MDD, including neuropathic pain, epilepsy, Huntington’s disease, and levodopa-induced dyskinesia associated with Parkinson’s disease and other disorders where modulation of the NMDA receptors, activation of AMPA pathways and/or key active metabolites of AV-101 may achieve therapeutic benefit.

About VistaStem
VistaStem Therapeutics is VistaGen’s wholly-owned subsidiary focused on applying human pluripotent stem cell (hPSC) technology, internally and with third-party collaborators, to discover, rescue, develop and commercialize (i) proprietary new chemical entities (NCEs), including small molecule NCEs with regenerative potential, for CNS and other diseases and (ii) cellular therapies involving stem cell-derived blood, cartilage, heart and liver cells. VistaStem’s internal drug rescue programs are designed to utilize CardioSafe 3D, its customized cardiac bioassay system, to develop small molecule NCEs for VistaGen’s pipeline. To advance potential regenerative medicine (RM) applications of its cardiac stem cell technology, in December 2016, VistaStem exclusively sublicensed to BlueRock Therapeutics LP, a next generation regenerative medicine company established in 2016 by Bayer AG and Versant Ventures, rights to certain proprietary technologies relating to the production of cardiac cells for the treatment of heart disease. In a manner similar to its exclusive sublicense agreement with BlueRock Therapeutics, VistaStem may pursue additional collaborations and potential RM applications of its stem cell technology platform, including using blood, cartilage, and/or liver cells derived from hPSCs, for (i) cell-based therapy, (ii) cell repair therapy, and/or (iii) tissue engineering.

For more information, please visit www.vistagen.com and connect with VistaGen on TwitterLinkedInand Facebook.

Forward-Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the successful launch, continuation and results of the NIMH’s Phase 2 (monotherapy) and/or the Company’s planned Phase 2 (adjunctive therapy) clinical studies of AV-101 in MDD, and other CNS diseases and disorders, including neuropathic pain and L-DOPA-induced dyskinesia associated with Parkinson’s disease, the potential for the Company’s stem cell technology to produce NCEs, cellular therapies, regenerative medicine or bone marrow stem cells to treat any medical condition, including autoimmune disorders and cancer, protection of its intellectual property, and the availability of substantial additional capital to support its operations, including the AV-101 clinical development activities described above. These and other risks and uncertainties are identified and described in more detail in VistaGen’s filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC’s website at www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.

Company Contact
Mark A. McPartland
VistaGen Therapeutics Inc.
Phone: +1 (650) 577-3600
Email: IR@vistagen.com

Investor Contact:
Valter Pinto / Allison Soss
KCSA Strategic Communications
Phone: +1 (212) 896-1254/+1 (212) 896-1267
Email: VistaGen@KCSA.com

Source: VistaGen Therapeutics, Inc.

BlueRock Therapeutics, Start-up based on UHN Technology, Expands Toronto Presence with R&D and Manufacturing Hub, Appoints Key R&D Leadership

Formalizes collaborations with McEwen Center for Regenerative Medicine at University Health Network, Centre for Commercialization of Regenerative Medicine

Appoints Michael Scott, Ph.D., as Senior Vice President of Product Development and Toronto Operations

TORONTO, Ontario and CAMBRIDGE, Mass., August 17, 2017 — BlueRock Therapeutics, which is developing cell-based therapies designed to alter the course of degenerative disease, today announces the expansion of the company’s presence in Toronto with a research, development and manufacturing site in the MaRS Discovery District. BlueRock has formalized its broad research collaboration with the Toronto-based McEwen Centre for Regenerative Medicine at University Health Network (UHN), as well as its manufacturing partnership with the Centre for Commercialization of Regenerative Medicine (CCRM). Additionally, Michael Scott, Ph.D., has been appointed by BlueRock as senior vice president of product development and Toronto operations. bluerock

“We are tremendously excited about our rapidly expanding presence in Toronto, and the addition of Dr. Scott.” said Emile Nuwaysir, Ph.D., president and CEO of BlueRock. “Our R&D model leverages collaborations with world-class stem cell and disease biology experts, and this UHN collaboration will allow us to work closely with leaders in the field to develop breakthrough cell therapies for patients suffering from heart failure. In addition, we have strengthened our strategic partnership with CCRM, which leverages not only their expertise, but also their new cGMP manufacturing facility to accelerate the buildout of BlueRock’s manufacturing capabilities.”

BlueRock’s collaboration with UHN will initially focus on the development of cell therapies that can regenerate heart muscle in patients who have had a heart attack or are suffering from chronic heart failure. BlueRock will work in collaboration with its scientific co-founder Gordon Keller, Ph.D., director of the McEwen Centre, and founding investigator Michael A. Laflamme, M.D., Ph.D., senior scientist, UHN, to further advance and translate breakthrough science into novel therapies derived from human pluripotent stem cells. Through its sponsored research collaboration with UHN, BlueRock will also pursue the potential of its cell therapies in a broad array of additional disease indications.

BlueRock’s research labs and centralized process development and manufacturing hub will be in a 10,000 square-foot state-of-the-art facility located just steps away from the CCRM cGMP manufacturing facility within Toronto’s MaRS Discovery District. BlueRock’s Toronto team is expected to move into the space later this year. The proximity of the BlueRock-UHN research collaboration to the CCRM manufacturing facility will make translation to clinical manufacture more straightforward, stepping up to clinical production levels as early as 2018.

The appointment of Michael Scott, Ph.D., as BlueRock’s senior vice president of product development brings to the company an entrepreneurial leader with more than 20 years of experience in the field of cardiovascular medical devices and in the stem cell therapeutics landscape. In addition to overseeing BlueRock’s Toronto operations, Dr. Scott will be part of the team focused on development of a cell therapy platform for delivery of dopaminergic neurons to treat Parkinson’s disease and cardiomyocytes to treat congestive heart failure. Prior to joining BlueRock, Dr. Scott served as chief development officer & vice president of R&D at ViaCyte, a clinical stage biotechnology company focused on the treatment of type I diabetes with a stem cell-based therapy product. Before ViaCyte, Dr. Scott was responsible for surgical heart valve therapy programs driving clinical trials at Edwards Lifesciences, and was the vice president of R&D at Orqis Medical, focused on treatment of congestive heart failure. He received a Ph.D. in medical biophysics from The University of Western Ontario, and masters and bachelor’s degrees in civil engineering from the University of Waterloo. Dr. Scott is part of a rapidly growing BlueRock team in Toronto, and the company expects the team to reach more than 30 members within a year.

“Joining the BlueRock team is a tremendous opportunity for me to be part of a company that has a groundbreaking vision of developing new products intended to transform medical care much in the same way that therapeutic monoclonal antibodies did,” said Dr. Scott. “I look forward to working with our premier scientific collaborators, as well as returning to my Canadian roots and integrating into the vibrant Toronto community.”

BlueRock launched in December 2016 through a $225 M Series A investment from Bayer AG and Versant Ventures, who support BlueRock’s vision to create breakthrough cell therapies. While the company’s platform approach can potentially be applied to many disease areas, BlueRock is initially focused on Parkinson’s and cardiac disease.

About BlueRock Therapeutics

Driven by a vision to liberate patients from the burden of degenerative disease, BlueRock Therapeutics is ushering in a new era of cell-based medicine that repairs the body when it cannot repair itself. Founded in 2016 through one of the largest Series A financings in biotech history, BlueRock and its team of preeminent scientists are pioneering cell therapies that replace dead, damaged or dysfunctional cells to restore critical natural functions in the body. Using an approach that can be applied to multiple diseases with great unmet need, BlueRock is initially targeting severe brain and heart conditions, with the goal of altering the course of disease and drastically improving quality of life. BlueRock’s culture is defined by scientific innovation, highest ethical standards and an urgency to bring transformative treatments to all who would benefit. For more information, visit www.bluerocktx.com.

Media Contact

Jessica Dyas

Canale Communications

jessica@canalecomm.com

619-849-5385